GH Stock Price Today (September 2026) — Guardant Health, Inc. Analysis & Key Metrics 2026-09-03
Guardant Health, Inc. (GH) is trading at $161.04, down 1.24% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $188.96 (17.3% upside).
- Volatility remains elevated (35.06% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (44.30% YoY) alongside significant competitive pressures.
GH Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Guardant Health, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $21.98B
P/E Ratio
Forward P/E: -359.49
Revenue Growth
Year over Year
Analyst Target
+17.3% upside potential
Key Investor Questions About GH
What investors need to know before buying
Based on current market data, GH presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 47.61)
- Fundamentals say: Mixed signals (nuanced financial profile)
GH's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for GH investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $1.70B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, GH stock traded between $53.40 and $176.58—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 35.06% annualized volatility and β=1.03, the stock exhibits moderate correlation to market moves—making GH suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Guardant Health (GH) Stock Could Trade At A 21% Discount Despite Patent Appeal
Guardant Health stock has delivered very strong gains over the past three years, yet its valuation signals are split, with the intrinsic value estimate pointing to upside while broader checks suggest the shares are not a clear bargain. After a recent legal setback and a sharp multi year rise, investors are weighing how much of Guardant Health’s growth potential is already reflected in the current price. Guardant Health has returned about 327.6% over the past three years, which puts more...
Did a US$245 Million Patent Ruling Just Shift Guardant Health's (GH) Investment Narrative?
In August 2026, a U.S. district court entered final judgment that Guardant Health infringed TwinStrand Biosciences and University of Washington DNA sequencing patents, ordering more than US$245.2 million in damages, accrued royalties and interest plus ongoing royalties on 11 products through March 2033. Guardant has said it will appeal and highlighted that updated versions of key tests, including Guardant Reveal and Shield, are excluded from the royalty order, while it continues to challenge...
Has Guardant Health (GH) Run Too Far After Its US$245 Million Patent Ruling?
Guardant Health (GH) is back in focus after a U.S. district court ordered the company to pay more than US$245.2 million in a patent dispute with TwinStrand Biosciences and the University of Washington. Guardant Health shares have been volatile around the legal headlines. The stock still has a 30 day share price return of 17.5% and a year to date share price return of 68.0%, while the 1 year total shareholder return of 169.17% and 3 year total shareholder return of more than 3x suggest...
Guardant Health ordered to pay $245M in patent dispute
A U.S. court ruled Guardant willfully infringed two core patents for DNA sequencing methods in a case brought by TwinStrand Biosciences and the University of Washington.
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
Guardant ordered to pay $245m in DNA sequencing patent dispute
Guardant plans to appeal the ruling, taking particular issue with a 6% ongoing royalties stipulate outlined in the court’s motion.
Guardant Health Dives After Losing A Patent Dispute; Judge Orders Royalties
Guardant Health stock tumbled Monday after losing a patent battle against privately held TwinStrand Biosciences.
What Is Really Moving Tempus AI Stock Right Now?
While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.
Hershey Company Upgraded, Toast, Inc. Downgraded: Updated Rankings on Top Blue-Chip Stocks
During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 161 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Up
Palantir, Freeport Clear Buy Points, Lead Five Stocks To Watch
Freeport-McMoRan and Palantir scored breakouts Friday, leading five stocks near buy points from a variety of sectors.
Explore More Analysis for GH
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Guardant Health, Inc.
Guardant Health, Inc. (GH) is currently trading at $161.04. The RSI (14-day) is at 47.6, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $188.96 implies 17.3% upside from current levels. Volatility is moderate at 35.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Guardant Health, Inc. (GH): The trailing P/E ratio is -46.68, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -359.49, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is -95.34. Price-to-Sales is 18.27. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering GH, the consensus price target is $188.96. This represents a 17.3% upside from the current price of $161.04. The range spans from a low target of $105.00 to a high target of $225.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Guardant Health, Inc. (GH) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Guardant Health, Inc. (GH) investors include: 1. Moderate volatility (35.1% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Guardant Health, Inc.'s (GH) current debt and financial health profile: Total debt stands at $1.70B. The current ratio is 4.03, indicating strong short-term liquidity. The quick ratio is 3.53. The company holds $1.05B in cash and equivalents. Free cash flow is positive at $26.61M, providing a cushion for debt servicing and shareholder returns.